The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Open accessAbstract
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance). Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both PDL-1 expression and TMB fail to encapsulate various tumor microenvironmental features influencing ICI responses15–17.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-treatment CD8+ T cell presence is linked to responses to ICB and anti-PD-1 plus lenvatinib in HCC patients.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We compared the tumor-associated immune infiltrates via multi-parameter immunohistochemistry (IHC) and observed a higher density of CD8+ T cells in baseline samples of R versus NR (p=0.04), consistent with prior reports (Fig. 4A and fig. S18) (18, 37).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [37]
In the citing paper
“Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [85].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [85]
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“An increase in CD8+ T cell proliferation within the tumor lesion and an increased frequency of Th9 cells in the patients’ circulation were also associated with treatment response (88, 91, 92).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“TILs are therefore under active investigation as a biomarker to guide selection of patients for treatment with ICT, although significant variability exists in definitions and thresholds (149, 150).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [149]
In the citing paper
“The presence of CD8+ T cells at tumor margins and within the tumor prior to treatment with checkpoint inhibitors was associated with a stronger response to treatment (Tumeh et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“abundance of T cells at the invasive tumor margin prior to treatment was associated with a better response, whereas upon treatment, T cell densities were increased both at the margin and within the tumor parenchyma in responding patients”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“In metastatic melanoma patients, a higher density of intratumoral CD8+ T cells at baseline was shown to predict favorable response to anti-PD-1 treatment”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Cited by
Sorted by citations
Items 601–700 of 1,060
Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebæk, E., Donia, M., Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01544-x · Cited by 215
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 222
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127515 · Cited by 203
“the tumor improves response to anti-PD1 therapy (65).”
BackgroundVassilakopoulou, M., Avgeris, M., Velcheti, V., Kotoula, V., Rampias, T., Chatzopoulos, K., Perisanidis, C., Kontos, C. K., Giotakis, A. Ι., Scorilas, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1543 · Cited by 218
Becht, É., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent‐Puig, P., Zucman‐Rossi, J., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 224
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M. T., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 216
Zemek, R. M., de Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 213
“Similarly, the absence of a STAT1 gene signature (30) in human pretreatment samples was associated with a decreased progression-free survival in the urothelial cancer/atezolizumab clinical dataset (fig.”
BackgroundInfluentialJoshi, K., de Massy, M. R., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., Hatipoglu, E., Oakes, T., Rosenthal, R., Peacock, T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0592-2 · Cited by 214
Lymphatic vessels regulate immune microenvironments in human and murine melanoma
Lund, A. W., Wagner, M., Fankhauser, M., Steinskog, E. S. S., Broggi, M. A. S., Spranger, S., Gajewski, T. F., Alitalo, K. K., Eikesdal, H. P., Wiig, H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci79434 · Cited by 218
Complementing the Cancer-Immunity Cycle
Pı́o, R., Ajona, D., Ortiz‐Espinosa, S., Mantovani, A., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00774 · Cited by 217
Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Joseph, E. L. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 212
Kelly, C. M., Antonescu, C. R., Bowler, T. G., Munhoz, R. R., Chi, P., Dickson, M. A., Gounder, M. M., Keohan, M. L., Movva, S., Dholakia, R., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6152 · Cited by 212
Emerging role of PTEN loss in evasion of the immune response to tumours
Vidotto, T., Melo, C. M., Castelli, E. C., Koti, M., dos Reis, R. B., & Squire, J. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0834-6 · Cited by 211
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z. F., He, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1022 · Cited by 213
Williams, J. B., Horton, B. L., Zheng, Y., Duan, Y., Powell, J. D., & Gajewski, T. F. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160485 · Cited by 213
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Nathanson, T., Ahuja, A., Rubinsteyn, A., Aksoy, B. A., Hellmann, M. D., Miao, D., Allen, E. M. V., Merghoub, T., Wolchok, J. D., Snyder, A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0019 · Cited by 211
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 209
“More than a few clinical trials have examined anti-PD-L1/2 alone or in combination with anti–PD-1 mabs [4,5,74,75].”
BackgroundCancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jérusalem, G., Hubert, P., & Herfs, M. F. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 224
High endothelial venules (HEVs) in immunity, inflammation and cancer
Blanchard, L., & Girard, J. (2021) · Angiogenesis · doi:10.1007/s10456-021-09792-8 · Cited by 231
Rivino, L., Bert, N. L., Gill, U. S., Kunasegaran, K., Cheng, Y., Tan, D., Becht, É., Hansi, N. K., Foster, G. R., Su, T., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci92812 · Cited by 208
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
Xiong, D., Wang, Y., & You, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18546-x · Cited by 208
Zhu, J., Fan, Y., Xiong, Y., Wang, W., Chen, J., Xu, S., Xia, Y., Jiang, R., Ma, S., Lei, J., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00896-9 · Cited by 215
Antonios, J. P., Soto, H., Everson, R. G., Moughon, D., Orpilla, J. R., Shin, N. P., Sedighim, S., Treger, J., Odesa, S., Tucker, A., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now287 · Cited by 206
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
Kardos, J., Chai, S., Mose, L. E., Selitsky, S. R., Krishnan, B., Saito, R., Iglesia, M. D., Milowsky, M. I., Parker, J. S., Kim, W. Y., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85902 · Cited by 207
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J., Lee, S., Ahn, J. S., Cheon, J., Min, Y. J., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 211
“Other biomarkers, including tumor mutation burden (16), mismatch repair deficiency (17), immune microenvironment (18, 19), RNA signatures in tumor tissues (20), combinations ofmultiple clinicopathologic factors (21), and baseline monocyte frequency (22), have also been proposed as biomarkers for predicting the respons…”
BackgroundChauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 205
“While the immune checkpoint blocker mixture alone also induced recruitment of leukocytes, particularly CD8+ and CD4+ T lymphocytes, and activation of CD8+ T lymphocytes as consistent with previous reports (45, 46), the combination of the TMA-ARB with the immune checkpoint blocker mixture also reduced CD8+ T lymphocyte…”
ResultYu, J. W., Bhattacharya, S., Yanamandra, N., Kilian, D., Shi, H., Yadavilli, S., Katlinskaya, Y. V., Kaczynski, H., Conner, M., Benson, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206223 · Cited by 204
IDO Expression in Cancer: Different Compartment, Different Functionality?
Meireson, A., Devos, M., & Brochez, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.531491 · Cited by 215
“Such T-cell inflamed–also termed immunologically “hot” –tumors have been associated with higher response rates to anti-PD1 immunotherapy (122).”
BackgroundChelvanambi, M., Fecek, R. J., Taylor, J. L., & Storkus, W. J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001906 · Cited by 206
Applications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 207
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 207
Ni, K., Aung, T., Li, S., Fatuzzo, N., Liang, X., & Lin, W. (2019) · Chem · doi:10.1016/j.chempr.2019.05.013 · Cited by 205
RetractedTreatment of Advanced Prostate Cancer—A Review of Current Therapies and Future PromisePreprint
Sumanasuriya, S., & Bono, J. S. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 213
Liu, X.-D., Hoang, A. G., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., Germán, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 207
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 206
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper, K. A., Carvajal‐Hausdorf, D., McLaughlin, J. F., Altan, M., Velcheti, V., Gaule, P., Sanmamed, M. F., Chen, L., Herbst, R. S., & Rimm, D. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0150 · Cited by 202
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 205
Webb, J. R., Milne, K., & Nelson, B. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0239 · Cited by 210
Masucci, G. V., Cesano, A., Hawtin, R. E., Janetzki, S., Zhang, J., Kirsch, I. R., Dobbin, K. K., Alvarez, J. D., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 200
Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., Wang, X., Ke, L., & Shi, K. (2018) · Theranostics · doi:10.7150/thno.29431 · Cited by 200
Kluger, H. M., Zito, C. R., Barr, M. L., Baine, M. K., Chiang, V., Sznol, M., Rimm, D. L., Chen, L., & Jilaveanu, L. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3073 · Cited by 202
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_67 · Cited by 200
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 206
Self-citationYe, L., Park, J. J.-Y., Dong, M. B., Yang, Q., Chow, R. D.-W., Peng, L., Du, Y., Guo, J., Dai, X., Wang, G., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0246-4 · Cited by 200
Anagnostou, V., Niknafs, N., Marrone, K. A., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 204
Ranki, T., Pesonen, S. A., Hemminki, A., Partanen, K. P. L., Kairemo, K., Alanko, T., Lundin, J. E., Linder, N., Turkki, R., Ristimaki, A. P., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0121-5 · Cited by 204
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Georgiou, K. E., Chen, L., Berglund, M., Ren, W., de Miranda, N. F. C. C., Lisboa, S., Fangazio, M., Zhu, S., Hou, Y., Wu, K., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686550 · Cited by 207
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Mercier, I. L., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 200
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R. E., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 202
Forschner, A., Battke, F., Hadaschik, D., Schulze, M., Weißgraeber, S., Han, T., Kopp, M., Frick, M., Klumpp, B. D., Tietze, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0659-0 · Cited by 215
“Among patients treated with pembrolizumab, presence of liver metastases at treatment initiation was found to be associated with significant reduced response rates and progressionfree survival, possibly due to reduced CD8 T-cell infiltration at invasive margins [9, 10].”
BackgroundHuman Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Egen, J. G., Ouyang, W., & Wu, L. C. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.010 · Cited by 198
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento‐Ribeiro, A. B., García‐Aranda, M., & Rivas, J. D. L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 202
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197
Predictors of responses to immune checkpoint blockade in advanced melanoma
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00608-2 · Cited by 200
Self-citationExisting and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Tumor-derived exosomes induce CD8+ T cell suppressors
Maybruck, B. T., Pfannenstiel, L. W., Díaz-Montero, M., & Gastman, B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0269-7 · Cited by 197
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 205
Opposing Roles of Type I Interferons in Cancer Immunity
Boukhaled, G. M., Harding, S. M., & Brooks, D. G. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 208
Immune Resistance in Lung Adenocarcinoma
Σπέλλα, Μ., & Stathopoulos, G. T. (2021) · Cancers · doi:10.3390/cancers13030384 · Cited by 196
“Usually PD-L1 expression is restricted at the invasive margin of the tumor, an area with abundant T cells, suggesting that PD-L1 expression is a counteracting mechanism adopted by tumor cells as a consequence of the presence of tumor antigen-specific T cells [77,78].”
BackgroundResistance mechanisms to immune checkpoint inhibitors: updated insights
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 226
“…clinical efficacy of ICIs has been positively correlated with T cell-derived biomarkers including the pre-exist-ence of CD8 + cytotoxic T cells at the invasive tumor margin and within the tumor, close proximity of PD-1 + cells and PD-L1 + cells in addition to the clonal T cell repertoire [46, 144].”
Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma
Lin, G. L., Nagaraja, S., Filbin, M. G., Suvà, M. L., Vogel, H. S., & Monje, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0553-x · Cited by 202
Valpione, S., Mundra, P. A., Galvani, E., Campana, L. G., Lorigan, P. C., Rosa, F. D., Gupta, A., Weightman, J., Mills, S. C., Dhomen, N. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24343-x · Cited by 198
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 198
Park, Y., Kuen, D., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 198
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y., Lee, H., Hsu, J. L., Yu, D., & Hung, M. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 198
TGF-β Signaling and Resistance to Cancer Therapy
Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 204
“Although cancer immunotherapy has made impressive progress in the treatment of a number of solid tumors and hematologic malignancies (Tumeh et al., 2014; Cristescu et al., 2018; Rodig et al., 2018), challenges persist as only a subset of patients with solid tumors are able to benefit from immunotherapy, owing to multi…”
BackgroundThe untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia · doi:10.1038/leu.2015.79 · Cited by 192
Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., Connelly, C. F., Pak, C. J., Carey, C. D., Daadi, S. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0201 · Cited by 192
Molecular approaches for classifying endometrial carcinoma
Piulats, J. M., Guerra, E., Gil-Martín, M., Roman‐Canal, B., Gatius, S., Pamplona, R. S., Velasco, A., Vidal, A., & Matías‐Guiu, X. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.015 · Cited by 197
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide
Remark, R., Merghoub, T., Grabe, N., Litjens, G. J. S., Damotte, D., Wolchok, J. D., Mérad, M., & Gnjatic, S. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf6925 · Cited by 188
Current state of immunotherapy for non-small cell lung cancer
Malhotra, J. D., Jabbour, S. K., & Aisner, J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.01 · Cited by 193
Gettinger, S. N., Choi, J., Mani, N. L., Sanmamed, M. F., Datar, I. J., Sowell, R., Du, V. Y., Kaftan, E. J., Goldberg, S. B., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 188
Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery
Large, D. E., Soucy, J. R., Hebert, J. M., & Auguste, D. T. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800091 · Cited by 194
Role of the immunosuppressive microenvironment in immunotherapy
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.018 · Cited by 202
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O. E., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 194
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 191
Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma
Rohr‐Udilova, N., Klinglmueller, F., Schulte‐Hermann, R., Stift, J., Herac, M., Salzmann, M., Finotello, F., Timelthaler, G., Oberhuber, G., Pinter, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24437-5 · Cited by 190
Role of the tumor microenvironment in pancreatic cancer
Murakami, T., Hiroshima, Y., Matsuyama, R., Homma, Y., Hoffman, R. M., & Endo, I. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12225 · Cited by 196
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G. D., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 193
“Several studies encompassing multiple tumor types have demonstrated that the ability of CD8+ T cells to infiltrate into the malignant portions of a tumor confers both improved overall survival and favorable response to ICI therapy (9, 19, 20).”
BackgroundSelf-citationNakao, S., Arai, Y., Tasaki, M., YAMASHITA, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 192
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 202
Li, H. Y., McSharry, M. V., Bullock, B., Nguyen, T. T., Kwak, J., Poczobutt, J. M., Sippel, T. R., Heasley, L. E., Weiser-Evans, M. C. M., Clambey, E. T., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0365 · Cited by 193
Burugu, S., Gao, D., Leung, S. C. Y., Chia, S., & Nielsen, T. O. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx557 · Cited by 193
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy
Medler, T. R., Murugan, D., Horton, W. R., Kumar, S., Cotechini, T., Forsyth, A. M., Leyshock, P., Leitenberger, J. J., Kulesz-Martin, M. F., Margolin, A. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.003 · Cited by 190
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Hammerich, L., Binder, A. F., & Brody, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.016 · Cited by 188
Mullins, S., Vasilakos, J. P., Deschler, K., Grigsby, I. F., Gillis, P. A., John, J., Elder, M. J., Swales, J. G., Timosenko, E., Cooper, Z. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0724-8 · Cited by 188
Woller, N., Gürlevik, E., Fleischmann-Mundt, B., Schumacher, A., Knocke, S., Kloos, A., Saborowski, M., Geffers, R., Manns, M. P., Wirth, T. C., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.115 · Cited by 189
Newman, J. H., Chesson, C. B., Herzog, N. L., Bommareddy, P. K., Aspromonte, S. M., Pepe, R., Estupinian, R., Aboelatta, M., Buddhadev, S., Tarabichi, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904022116 · Cited by 192
“4H and Dataset S2), a therapy-induced change previously reported in patients responding to PD-1 checkpoint blockade (32).”
ResultCombining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber, H., Sapra, P., Loganzo, F., & May, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.008 · Cited by 188
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L. M., Yu, H., Ellison, K. E., Kowalewski, A. A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 187
Thomas, A., Vilimas, R. J., Trindade, C. J., Erwin-Cohen, R. A., Roper, N., Xi, L., Krishnasamy, V. P., Levy, E. B., Mammen, A., Nichols, S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.026 · Cited by 186
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
“showed that TILs with less diversity were significantly associated with clinical response to pembrolizumab in melanoma patients (21).”
BackgroundInfluentialImmunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 191
Self-citationBiomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 195
“The hot TME seen in adaptive immune resistance, but not the cold TME seen in innate immune resistance, is associated with response to PD-1 pathway inhibition [32].”
BackgroundLiu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
Rajani, K. R., Parrish, C., Kottke, T. J., Thompson, J., Zaidi, S., Ilett, E. J., Shim, K. G., Díaz, R. M., Pandha, H., Harrington, K. J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.156 · Cited by 189
Metadata
- Authors
- Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inserm (FR)
- Adaptive Biotechnologies (United States) (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Tumeh, Paul C.
- Ribas, Antoni
- ORCID
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 568-571
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4246418
- OpenAlex
- W2039123767
- Semantic Scholar
- 2c96ca62d538ff43fce01bc848fc018f6ae2b4a0
- Cited by
- 6,609
- References
- 24
- Citations by year
- 2026: 280 · 2025: 398 · 2024: 491 · 2023: 588 · 2022: 695 · 2021: 768 · 2020: 800 · 2019: 610 · 2018: 593 · 2017: 566 · 2016: 488 · 2015: 303 · 2014: 12
- FWCI
- 220.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- American Association for Cancer Research (SU2C-AACR-DT1012)
- Cancer Research Institute (SU2C-AACR-DT1012, CA16042)
- Melanoma Research Alliance (SU2C-AACR-DT1012)
- Adaptive Biotechnologies
- Institut Gustave-Roussy
- Sociedad Española de Oncología Médica
- National Institutes of Health (UL1TR000124, 5u54ca119347-03, P30 CA- 16042, SU2C-AACR-DT1012, CA16042)
- Stand Up To Cancer (SU2C-AACR-DT1012))
- National Cancer Institute (U54-CA119347, P01CA168585, P30-CA16042, R01CA170689, P30CA016042)
- National Institute of Allergy and Infectious Diseases (K08AI091663)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pembrolizumab, adaptive immune resistance, CD8+ T cells, PD-L1, PD-1/PD-L1 axis, metastatic melanoma, tumor-infiltrating lymphocytes, T cell receptor repertoire, predictive biomarkers, tumor regression, immune checkpoint inhibitors
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Biomarkers, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation, Adaptive Immunity, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
